Видео ютуба по тегу Azacytidine

Dr. Saunthararajah on Mechanisms of Resistance to 5-Azacytidine/Decitabine in MDS-AML
Dr. Saunthararajah on Mechanisms of Resistance to 5-Azacytidine/Decitabine in MDS-AML
Venetoclax plus azacitidine for higher-risk MDS
Venetoclax plus azacitidine for higher-risk MDS
Venetoclax and 5-azacytidine for the treatment of MDS and CMML
Venetoclax and 5-azacytidine for the treatment of MDS and CMML
Combination therapies with azacitidine for MDS
Combination therapies with azacitidine for MDS
Novel HCK inhibitor has a synergistic effect with azacytidine or cytarabine in AML cells
Novel HCK inhibitor has a synergistic effect with azacytidine or cytarabine in AML cells
Phase IB/II Study of Nivolumab in Combination with Azacytidine ...
Phase IB/II Study of Nivolumab in Combination with Azacytidine ...
Phase I trial results for oral azacitidine and venetoclax in R/R AML
Phase I trial results for oral azacitidine and venetoclax in R/R AML
Maintenance venetoclax and 5-azacytidine in patients with AML
Maintenance venetoclax and 5-azacytidine in patients with AML
Mechanisms of Resistance to 5-Azacytidine/Decitabine in MDS-AML
Mechanisms of Resistance to 5-Azacytidine/Decitabine in MDS-AML
Determining the Mechanism of 5-Azacytidine Resistance... - Kieran O'Neill - RegGen - ISMB/ECCB 2017
Determining the Mechanism of 5-Azacytidine Resistance... - Kieran O'Neill - RegGen - ISMB/ECCB 2017
5-Azacytidine: A DNA Demethylating Agent with Therapeutic Potential in Cancer Treatment | GlpBio
5-Azacytidine: A DNA Demethylating Agent with Therapeutic Potential in Cancer Treatment | GlpBio
Prof. Charles Craddock | RAvVA study: molecular predictors of response to azacytidine
Prof. Charles Craddock | RAvVA study: molecular predictors of response to azacytidine
Serge Verstovsek, MD on the Phase 2 Study Involving Ruxolitinib with Azacytidine
Serge Verstovsek, MD on the Phase 2 Study Involving Ruxolitinib with Azacytidine
GC10946 5-Azacytidine
GC10946 5-Azacytidine
Rationale of OMNIVERSE: oral azacitidine + venetoclax in patients with R/R or newly diagnosed AML
Rationale of OMNIVERSE: oral azacitidine + venetoclax in patients with R/R or newly diagnosed AML
Trial To Evaluate Eprenetapopt-Azacytidine Combo in TP53+ MDS Completes Enrollment
Trial To Evaluate Eprenetapopt-Azacytidine Combo in TP53+ MDS Completes Enrollment
5-Azacytidine in Combination with Ruxolitinib As Therapy for Patients with MDS/MPN
5-Azacytidine in Combination with Ruxolitinib As Therapy for Patients with MDS/MPN
Phase Ib/II study of nivolumab in combination with azacytidine in patients with relapsed AML
Phase Ib/II study of nivolumab in combination with azacytidine in patients with relapsed AML
Phase IB/II Study of Nivolumab with Azacytidine in Patients with Relapsed AML
Phase IB/II Study of Nivolumab with Azacytidine in Patients with Relapsed AML
Venetoclax + Azacitidine in Frontline AML Management
Venetoclax + Azacitidine in Frontline AML Management